210 publications
Name | Date | Type | Actions |
---|---|---|---|
2006 Financial Report Le chiffre d’affaires s’est accru de 7,6% par rapport à l’exercice précédent. |
04/06/2007 | Public releases | |
2008 annual earnings The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements. |
31/03/2009 | Public releases | |
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
22/07/2008 | Public releases | |
2008 revenue: €234.4 M Revenue grew in 2008, despite poor economic conditions in the second half and |
22/01/2009 | Public releases | |
2009 annual earnings March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements. |
31/03/2010 | Public releases | |
2009 Revenue improvement in trends in the first quarter Vétoquinol’s revenue for the first quarter of 2009 reached €57.1 M, an increase of 4.4% over the first quarter of 2008. |
09/04/2009 | Public releases | |
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
2011 annual earnings Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements. |
03/04/2012 | Public releases | |
2011, a year of transition Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis. |
24/01/2012 | Public releases | |
2012 sales up 5.0% Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%. |
24/01/2013 | Public releases | |
2012, return to growth Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements. |
26/03/2013 | Public releases | |
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
24/10/2013 | Public releases | |
2013 growth driven by reference products Lure (France), March 12, 2014 – At its March 11, 2014 meeting, the Vétoquinol SA board of directors reviewed the Group results and approved the 2013 financial statements. |
12/03/2014 | Public releases | |
2014 sales up 5.2% to €315.3 million The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014. |
22/01/2015 | Public releases | |
2015 results sales of reference products up 9.4% ebit up 10.3% At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements. |
21/03/2016 | Public releases | |
2015 sales up 8.7% to €342.6 million The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound. |
08/02/2016 | Public releases | |
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
26/01/2017 | Public releases | |
2017 sales: €352.2 million 7.6% like-for-like growth in essentials products The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%. |
23/01/2018 | Public releases | |
2018 sales: up 3.2% to €367.9 million 9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
|
24/01/2019 | Public releases | |
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
26/03/2020 | Public releases | |
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
23/01/2020 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales) At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
30/07/2020 | Public releases | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
2021 Annual results ALL FINANCIAL INDICATORS UP. |
24/03/2022 | Public releases | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
15/09/2022 | Public releases | |
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
23/09/2022 | Public releases , Half Year Report | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
25/10/2007 | Public releases | |
7.8% organic growth in Q4 2013 The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012. |
23/01/2014 | Public releases | |
Activity Report 2006 |
04/06/2007 | Public releases | |
All key financial indicators up in 2016 At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. |
22/03/2017 | Public releases | |
Annual earnings for 2006: a year of good performance |
23/04/2007 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Availability of the 2019 universal registration document Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020. |
23/04/2020 | Public releases | |
Availability of the 2020 universal registration document Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021. |
28/04/2021 | Public releases | |
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
22/04/2022 | Public releases | |
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
13/04/2023 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
Bilan annuel des moyens alloués au contrat de liquidité (décembre 2021) Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2021 |
04/01/2022 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité - french Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 30 juin 2019 |
03/07/2019 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité - french Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2019 |
06/01/2020 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité - french Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020 |
05/01/2021 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité - french Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 30 juin 2020 |
02/07/2020 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité - french Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020 |
05/07/2021 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2007) - french Au 30 juin 2007 |
06/07/2007 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2008) - french Au 30 juin 2008 |
10/07/2008 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2008) - french Au 31 décembre 2008 |
12/01/2009 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2009) - french Au 30 juin 2009 |
09/07/2009 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2009) - french Au 31 décembre 2009 |
05/01/2010 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2010) - french Au 30 juin 2010 : |
07/07/2010 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2010) - french Au 31 décembre 2010 |
10/01/2011 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2011) - french Au 31 décembre 2011 |
13/01/2012 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2012) - french Au 30 juin 2012 |
16/07/2012 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2012) - french Au 31 décembre 2012 |
16/01/2013 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2013) - french Au 30 juin 2013 |
08/07/2013 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2013) - french Au 31 décembre 2013 |
16/01/2014 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2014) - french Au 30 juin 2014 |
08/07/2014 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2014) - french Au 31 décembre 2014 |
06/01/2015 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2015) - french Au 31 décembre 2015 |
16/01/2016 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2015) - french Au 30 juin 2015 |
08/07/2015 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french Au 31 décembre 2016 |
05/07/2018 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french Au 31 décembre 2016 |
07/01/2019 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french Au 31 décembre 2016 |
02/01/2017 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2016) - french Au 30 juin 2016 |
12/07/2016 | Liquidity contract | |
Bilan semestriel des moyens alloués au contrat de liquidité (2017) - french Au 30 juin 2017 |
25/07/2017 | Liquidity contract | |
BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle. |
30/06/2010 | Public releases | |
Business is strong in first-half of 2007 : + 12.9% 2007 Half year Financial Report |
26/07/2007 | Public releases | |
Buyback programs - April 2024 Monthly communication regarding buyback programs |
06/05/2024 | Liquidity contract | |
Combined ordinary and extraordinary general meeting May 21, 2019 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin. |
22/05/2019 | Public releases | |
Combined ordinary and extraordinary general meeting May 29, 2018 The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin. |
29/05/2018 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french) Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites |
30/07/2015 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 (french) Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016 |
28/07/2016 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 (french) Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017 |
27/07/2017 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth. |
16/07/2010 | Public releases | |
Covid-19: Vetoquinol donates masks to neighboring healthcare facilities Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions. |
20/03/2020 | Public releases | |
Departure of Pierre Konareff April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre |
14/04/2010 | Public releases | |
Dominique Derveaux appointed Group Chief Operations Officer
Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin. |
28/04/2020 | Public releases | |
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
20/01/2022 | Public releases | |
Dynamic first half 2016 2016 Half year Financial Report |
28/07/2016 | Public releases | |
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
18/03/2008 | Public releases | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
First half 2015 sales €167.2m, up 11.9% The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements. |
30/07/2015 | Public releases | |
First half 2018 results At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements. |
26/07/2018 | Public releases | |
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
25/07/2019 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
Flevox® the new parasiticide for dogs and cats Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets. |
14/02/2012 | Public releases | |
Forcyl® - a booming brand Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs. |
14/11/2012 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases | |
Growth in Revenues in the first half of 2009 Vétoquinol’s revenues in the first half of 2009 totalled EUR 119.9 million, an increase of 2.7% compared to the first half of the preceding year. |
16/07/2009 | Public releases | |
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
20/07/2022 | Public releases | |
Information relative à un engagement du Conseil d’Administration pris au bénéfice du Directeur Général Délégué Groupe (french) Lors de sa réunion du 13 mars 2009, le Conseil d’Administration a pris l’engagement, dans le cadre de la loi du 21 août 2007, de verser une indemnité à Monsieur Dominique HENRYON, Directeur Général Délégué Groupe, en cas de révocation de ce dernier pour tout autre motif qu’une faute grave. Cette décision se substitue à celle du 1er décembre 1998. |
30/03/2009 | Public releases | |
Information relative au code de gouvernance Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF. |
20/12/2014 | Public releases |